The National Institutes of Health on Monday announced a sweeping initiative to revamp the way it manages data in an effort to foster the adoption of artificial intelligence, supercomputing and other technologies poised to transform medical research.
With more than 90% of the biopharmaceutical industry made up of small, emerging companies, it is important for BIO to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be impacting the industry’s ability to maintain a robust pipeline of innovative medicines. The ability to access capital and form strategic alliances is vital for small therapeutic-focused companies to succeed in translating novel drug candidates into approved medical products for patients.
The conference is aimed at bringing together global companies to showcase the successes and future innovation of the innovative medicines manufacturing sector, which is already worth £30 billion to the economy.
The National Institutes of Health (NIH) invests nearly $37.3 billion annually in medical research. More than 80% of the funding is awarded through nearly 50,000 competitive grants to more than 300,000 researchers at more than 2500 universities, medical schools, and other research institutions in every U.S. state and around the world.
Renowned worldwide for its technological prowess in fields like cybersecurity, artificial intelligence, IT, and smart mobility, Israel is also continuing to gain recognition for its invaluable contributions to the worlds of biotechnology and the life sciences – technologies which help improve healthcare and quality of life for millions worldwide.
Tuesday, June 19, 2018 – 5:30 p.m. – 7:30 p.m. EST
It’s been a wonderful spring for Women In Bio in Baltimore. Local organizers have put on amazing morning meet-ups featuring outstanding women scientists-entrepreneurs and business leaders. Let’s cap off this “season” with a Capital Region chapter-wide event. At this evening mixer, we’ll get to know each other more and meet new people in the bio scene in Baltimore and beyond.
Skim the headlines, and you might get the impression that the biotech startup world revolves around an insider’s club of Midas-listed venture capitalists.
Not true.
Risk management has become a top-of-mind issue for C-suites and boards around the world—nowhere more than in pharmaceutical companies. In a politically and economically turbulent environment, the risks pharma companies face, especially in clinical-trial design and execution, drug approval, product quality, and global commercial practices, are increasing in both frequency and magnitude.
REMINDER – CARB-X’s 2018 Funding Round 2 is now open for applications until June 8, 2018 at 5 PM EST
Apply now!
CARB-X 2018 Funding Round 2 is open for applications until June 8, 2018, 5 PM EST. Expressions of Interest are welcome on-line only.
The scope of Round 2 funding is broad and includes therapeutics, vaccines, microbiome, diagnostics and other life-saving products for certain drug-resistant and difficult-to-treat pathogens.
Detailed information about the scope of Round 2 can be found here.
Information about how to apply for CARB-X funding can be found here. The on-line link to submit an Expression of Interest is now live, and will be live until June 8 at 5 PM EST.
Healthcare focused startups and government agencies got together in the same room here for HHS Startup Day and each group brought some hard-earned advice for the other.